Indication
FGFR2 Gene Mutation
7 clinical trials
7 products
Product
RLY-4008Clinical trial
A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Product
BGJ398Clinical trial
A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib Versus Gemcitabine With Cisplatin in Subjects With Advanced/Metastatic or Inoperable Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations: The PROOF TrialStatus: Terminated, Estimated PCD: 2023-03-02
Product
GemcitabineProduct
CisplatinClinical trial
A Phase II, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) Tablet in Adult Patients With Advanced CholangiocarcinomaStatus: Completed, Estimated PCD: 2024-02-28
Product
TT-00420Clinical trial
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving ErdafitinibStatus: Terminated, Estimated PCD: 2022-12-20
Product
BalversaClinical trial
A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients With Advanced or Metastatic Cholangiocarcinoma With FGFR2 Gene Fusions or Other FGFR Genetic Alterations Who Failed or Are Intolerant to Platinum-based ChemotherapyStatus: Terminated, Estimated PCD: 2021-03-01
Clinical trial
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR AlterationsStatus: Active (not recruiting), Estimated PCD: 2022-05-13
Product
PemigatinibClinical trial
A Phase II Study of Pemigatinib After Curative Local Therapy in Locally Advanced Intrahepatic Cholangiocarcinoma (iCCA) Harboring FGFR2 Fusions/Rearrangements.Status: Recruiting, Estimated PCD: 2025-11-01